Ovid Therapeutics (OVID) appoints kevin Norrett as chief business officer. Published on July 14, 2026 at 6:33 am by jeff lewis in news. On July 8, 2026, Ovid Therapeutics Inc. (NASDAQ:OVID) announced several strategic appointments. Kevin Norrett will join Ovid as chief business officer to lead business and corporate development functions, as well as strategic partnerships. Most recently, Norrett served as chief business officer at Soleno Therapeutics. Ovid also promoted Charles Carter to CFO, where Carter will lead business and financial operations. Carter succeeds Jeffrey Rona, who will remain a long-term advisor to the company through 2027. Victoria Fort was promoted to chief strategy officer, leading enterprise strategy, investor relations, and operational growth initiatives. In May, Ovid Therapeutics reported Q1 EPS of (12c), compared with the consensus of (11c). CEO Meg Alexander said the first quarter reflected "focused execution" and continued progress across the company's pipeline of small molecule medicines for intractable brain conditions. Alexander said development programs remain on track, the clinical organization has expanded, and the company expects to be well capitalized into 2029. Ovid Therapeutics Inc. (NASDAQ:OVID) develops small-molecule medicines for brain disorders, including epilepsies and seizure-related neurological disorders in the United States. While we acknowledge the risk and potential of OVID as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than OVID and that has 10,000% upside potential, check out our report about the cheapest AI stock.

Soleno Therapeutics presents data on VYKAT XR for Prader-Willi syndrome at ENDO 2026. Soleno Therapeutics, a Neurocrine Biosciences company, announced on June 15 new late-breaking data at ENDO 2026 showing that resuming treatment with VYKAT XR (diazoxide choline) extended-release tablets for two years after a 16-week randomized withdrawal period was associated with durable improvements in hyperphagia and behavioral symptoms in individuals with Prader-Willi syndrome. Sanjay Keswani, M.D., Chief Medical Officer of Neurocrine Biosciences, said, "These compelling data further reinforce our confidence in VYKAT XR as a safe and effective long-term treatment for hyperphagia in individuals four years of age and older living with Prader-Willi syndrome. Individuals who resumed treatment following the randomized withdrawal period achieved durable improvements in hyperphagia and other PWS-related behaviors. This completes the presentation of data from our comprehensive Phase 3 development program and further confirms the long-term benefit of VYKAT XR for people living with PWS." The Phase 3 development program included Study C614, an open-label long-term extension study enrolling 77 participants. The study assessed whether those who had received placebo during the withdrawal period could regain benefit after restarting VYKAT XR and whether those who remained on continuous therapy maintained improvement over time. Hyperphagia was measured using the Hyperphagia Questionnaire for Clinical Trials (HQ-CT), while behavioral symptoms were assessed by the PWS Profile questionnaire (PWSP). Results showed that participants resuming VYKAT XR experienced recovery of benefit, while those continuing therapy maintained improvements. Additional presentations compared outcomes from VYKAT XR-treated participants to natural history controls from the PATH for PWS Natural History Study. Over three years, statistically significant and sustained improvements were observed in hyperphagia scores at all evaluated time points (p<0.0001), with consistent benefits also reported across six behavioral domains such as anxiety, rigidity/irritability, compulsivity, aggressive behaviors, disordered thinking, and depression. Prader-Willi syndrome is described as a rare genetic neurodevelopmental disorder caused by abnormal gene expression on chromosome 15. The main symptom is hyperphagia - a persistent sensation of hunger leading to food preoccupations - which can severely affect quality of life and lead to additional health complications including diabetes or cardiovascular disease. VYKAT XR was approved by the U.S. Food and Drug Administration on March 26, 2025, for treating hyperphagia in adults and pediatric patients aged four years or older with Prader-Willi syndrome. Important safety information includes contraindications related to hypersensitivity to diazoxide or thiazides; warnings about risks such as hyperglycemia or fluid overload; monitoring recommendations; and common adverse reactions like hypertrichosis or edema.